Recombinant multi-species MAD2L1BP protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MAD2L1BP protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene was identified as a binding protein of the MAD2 mitotic arrest deficient-like 1 (MAD2/MAD2L1). MAD2 is a key component of the spindle checkpoint that delays the onset of anaphase until all the kinetochores are attached to the spindle. This protein may interact with the spindle checkpoint and coordinate cell cycle events in late mitosis. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]
The Alternative Names of target: 0610009D16Rik,2510031P20Rik,CMT2,CMT2A,CMT2B,Caught by MAD2 protein,MAD2L1-binding protein,MAD2L1BP,Mad2l1bp,Mad2lbp,mKIAA0110,p31(comet),p31comet
Go
to MAD2L1BP products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP13816-Ag-1/ GM-Tg-hg-IP13816-Ag-2 | Human MAD2L1BP protein | Human |
| GM-Tg-rg-IP13816-Ag-1/ GM-Tg-rg-IP13816-Ag-2 | Rat MAD2L1BP protein | Rat |
| GM-Tg-mg-IP13816-Ag-1/ GM-Tg-mg-IP13816-Ag-2 | Mouse MAD2L1BP protein | Mouse |
| GM-Tg-cynog-IP13816-Ag-1/ GM-Tg-cynog-IP13816-Ag-2 | Cynomolgus/Rhesus macaque MAD2L1BP protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP13816-Ag-1/ GM-Tg-felg-IP13816-Ag-2 | Feline MAD2L1BP protein | Feline |
| GM-Tg-cang-IP13816-Ag-1/ GM-Tg-cang-IP13816-Ag-2 | Canine MAD2L1BP protein | Canine |
| GM-Tg-bovg-IP13816-Ag-1/ GM-Tg-bovg-IP13816-Ag-2 | Bovine MAD2L1BP protein | Bovine |
| GM-Tg-equg-IP13816-Ag-1/ GM-Tg-equg-IP13816-Ag-2 | Equine MAD2L1BP protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP13816-Ag-1/ GM-Tg-hg-IP13816-Ag-2;
GM-Tg-rg-IP13816-Ag-1/ GM-Tg-rg-IP13816-Ag-2;
GM-Tg-mg-IP13816-Ag-1/ GM-Tg-mg-IP13816-Ag-2; GM-Tg-cynog-IP13816-Ag-1/ GM-Tg-cynog-IP13816-Ag-2; GM-Tg-felg-IP13816-Ag-1/ GM-Tg-felg-IP13816-Ag-2; GM-Tg-cang-IP13816-Ag-1/ GM-Tg-cang-IP13816-Ag-2; GM-Tg-bovg-IP13816-Ag-1/ GM-Tg-bovg-IP13816-Ag-2; GM-Tg-equg-IP13816-Ag-1/ GM-Tg-equg-IP13816-Ag-2 |
| Products Name | MAD2L1BP protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | MAD2L1BP |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MAD2L1BP protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.